Drug intelligence / Profile preview

INE-1001

Development stage: Preclinical
Lead developer: Innerva Pharmaceuticals
Modality: Small Molecules
Administration: Ophthalmic, Topical

Overview

INE-1001 is a small molecule drug candidate being developed by Innerva Pharmaceuticals for the treatment of Dry Eye Disease (DED). It is designed as a topical ophthalmic formulation that targets PIEZO2, a mechanosensitive ion channel. PIEZO2 is involved in sensing mechanical stimuli on the ocular surface, and its modulation is hypothesized to alleviate symptoms associated with DED, such as pain and discomfort. The drug is currently in the IND-enabling/preclinical stage of development.

Targets

PIEZO2 (Piezo2 mechanosensitive channel)

Beyond the preview

Go deeper on INE-1001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INE-1001.

Explore the full profile